Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD and Dasatinib With or Without Allogeneic Stem Cell Transplant in Ph+ and/or BCR-ABL+ ALL
NCT00792948Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2009
- Primary completion
- Jun 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by National Cancer Institute. Started Sep 2009; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00792948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792948.